Gene Logic Enters into Agreement with Gene Logic Enters into Agreement with Lilly to Discover New Development Paths for Multiple Clinical Drug Candidates

Gene Logic Inc. (NASDAQ: GLGC) announced today that it has entered into a drug repositioning and development agreement with Eli Lilly and Company to seek alternative development paths for multiple Lilly drug candidates. All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.

Source: Gene Logic Inc.